139 related articles for article (PubMed ID: 28024948)
1. Successful Treatment of Metastatic Upper Tract Urothelial Carcinoma With Vemurafenib: Case Report.
Ji G; Qian Y
Clin Genitourin Cancer; 2017 Aug; 15(4):e719-e721. PubMed ID: 28024948
[No Abstract] [Full Text] [Related]
2. Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor.
Kaplan HG
J Natl Compr Canc Netw; 2013 Dec; 11(12):1466-70. PubMed ID: 24335681
[TBL] [Abstract][Full Text] [Related]
3. A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib.
Maleka A; Åström G; Byström P; Ullenhag GJ
BMC Cancer; 2016 Aug; 16():634. PubMed ID: 27520988
[TBL] [Abstract][Full Text] [Related]
4. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.
Peyrade F; Re D; Ginet C; Gastaud L; Allegra M; Ballotti R; Thyss A; Zenz T; Auberger P; Robert G
Haematologica; 2013 Feb; 98(2):e20-2. PubMed ID: 23300174
[No Abstract] [Full Text] [Related]
5. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.
Lee EQ; Ruland S; LeBoeuf NR; Wen PY; Santagata S
J Clin Oncol; 2016 Apr; 34(10):e87-9. PubMed ID: 25092772
[No Abstract] [Full Text] [Related]
6. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
7. BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer.
Mesko SM; Rosenthal KJ; Boasberg PD; Hamid O
J Clin Oncol; 2015 Sep; 33(25):e101-3. PubMed ID: 24711550
[No Abstract] [Full Text] [Related]
8. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib.
Follows GA; Sims H; Bloxham DM; Zenz T; Hopper MA; Liu H; Bench A; Wright P; Van't Veer MB; Scott MA
Br J Haematol; 2013 Apr; 161(1):150-3. PubMed ID: 23278307
[No Abstract] [Full Text] [Related]
9. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.
Protsenko SA; Semionova AI; Komarov YI; Aleksakhina SN; Ivantsov AO; Iyevleva AG; Imyanitov EN
Invest New Drugs; 2015 Oct; 33(5):1136-43. PubMed ID: 26286452
[TBL] [Abstract][Full Text] [Related]
10. Sustained Response to Vemurafenib in a BRAF
Prager GW; Koperek O; Mayerhoefer ME; Muellauer L; Wrba F; Niederle B; Zielinski CC; Raderer M
Thyroid; 2016 Oct; 26(10):1515-1516. PubMed ID: 27532222
[No Abstract] [Full Text] [Related]
11. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.
Charles J; Beani JC; Fiandrino G; Busser B
J Am Acad Dermatol; 2014 Sep; 71(3):e97-9. PubMed ID: 25128147
[No Abstract] [Full Text] [Related]
12. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
[TBL] [Abstract][Full Text] [Related]
13. Targeting the BRAF V600E mutation in multiple myeloma.
Andrulis M; Lehners N; Capper D; Penzel R; Heining C; Huellein J; Zenz T; von Deimling A; Schirmacher P; Ho AD; Goldschmidt H; Neben K; Raab MS
Cancer Discov; 2013 Aug; 3(8):862-9. PubMed ID: 23612012
[TBL] [Abstract][Full Text] [Related]
14. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
15. [Vemurafenib (ZELBORAF
Shimada T; Yamaguchi K; Aoki T; Kajihara A; Mizui T
Nihon Yakurigaku Zasshi; 2016; 148(4):197-204. PubMed ID: 27725568
[No Abstract] [Full Text] [Related]
16. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.
Idbaih A; Mokhtari K; Emile JF; Galanaud D; Belaid H; de Bernard S; Benameur N; Barlog VC; Psimaras D; Donadieu J; Carpentier C; Martin-Duverneuil N; Haroche J; Feuvret L; Zahr N; Delattre JY; Hoang-Xuan K
Neurology; 2014 Oct; 83(16):1478-80. PubMed ID: 25209580
[No Abstract] [Full Text] [Related]
17. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
[TBL] [Abstract][Full Text] [Related]
20. Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation.
Ali SM; Miller VA; Ross JS; Pal SK
Eur Urol; 2015 Jun; 67(6):1195-1196. PubMed ID: 25630452
[No Abstract] [Full Text] [Related]
[Next] [New Search]
